BIO Europe 2024
Early-stage biopharma companies have traditionally had limited options for getting their first asset to market. In most cases, they pursue deals with larger partners and lose or limit rights to their asset, or become a fully integrated company through heavy investment and a great deal of risk.
There is now a third option: the leading integrated commercial delivery model. This pharma commercialization services model aims to increase efficiency, scale and speed by utilizing existing global infrastructure and significant expertise within Syneos Health and — importantly — enables customers to retain control of their assets longer to keep future options open.
We are also the ideal solution for biopharma companies seeking to launch in new markets, where they face multiple challenges that can make or break their success including resource constraints, risk exposure, the complexity of uncharted territory, and nonalignment across siloed and divergent stakeholders. We partner with purpose, focused on your performance, with an unmatched suite of globalization capabilities at your disposal, from strategic planning and communications to deployment solutions.
Meet with us at BIO-Europe 2024 to explore how Syneos Health can help you reach your potential.
Related Content
Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
WEBINAR | Adaptability: The Key to Accelerated Global Expansion
BLOG | The Key to Accelerated Global Expansion: Adaptability through a Flexible Outsourcing Model
Untapped Potential in Women’s Health: An Analysis of Gender Imbalance in Life Science Investment
Driving Commercial Success with Predictive Analytics and Agile Resourcing
Are You Building for Commercial Success? 2024 APAC Perspective
FT Live | De-Risking Investment to Deliver Innovation
FT Live | The Marriage of Biotech Innovators and Big Pharma: Bringing New Drugs to Market
